Skip to content
Log in / Sign up
Search

Trending Tickers: $FANG Midland Basin Deal, $SLS Leukemia Trial Win, $VG LNG Expansion

Trending Tickers

Stay Updated with Market Movers

· 3 min read

Category: Investing · Market Trends · Stock Insights

This week, several stocks caught investors’ attention, driven by significant developments and market momentum. Here’s the breakdown of this week’s trending stocks:

Diamondback Energy ($FANG) Expands in the Midland Basin

Diamondback Energy ($FANG) agreed to acquire certain Double Eagle businesses for $2.15 billion in cash and approximately 15.56 million Diamondback shares. The assets cover roughly 176,000 net acres in the Midland Basin of West Texas. Diamondback estimates they could produce about 35,000 barrels of oil per day in 2027, alongside natural gas and other liquids. The transaction is expected to close on December 21, subject to customary conditions.

The acquisition gives Diamondback a larger stake in acreage it already knows. Management said the deal buys out the 40% interest in a partnership it did not previously own and adds undeveloped drilling locations without requiring another rig or a material change to its development plan. Diamondback expects the transaction to increase cash flow and free cash flow per share, but those benefits depend on production, development costs, and commodity prices. It expects to fund the cash portion through a combination of existing cash and borrowing.

Stock Price Reaction

$FANG closed at $177.41 on Monday, November 16, down 4.07% from the previous trading day.

SELLAS Life Sciences ($SLS) Reports a Phase 3 Survival Benefit

SELLAS Life Sciences ($SLS) reported that its Phase 3 REGAL trial met its primary endpoint in patients with acute myeloid leukemia who had entered a second or later remission and could not undergo a stem-cell transplant. Patients receiving its experimental cancer vaccine, galinpepimut-S, had a median overall survival of 24.0 months, compared with 14.7 months for patients receiving the investigator’s choice of available treatment. SELLAS reported a 41% reduction in the risk of death over the study period.

Overall survival measures how long patients lived, making this a consequential result for a late-stage cancer trial. SELLAS said no new safety signals were identified and plans to discuss the data and a potential accelerated filing strategy with the FDA. It is preparing a marketing application for the first half of 2027. The treatment is not yet approved, and the company is still analyzing the trial’s secondary endpoints.

After Tuesday’s market close, SELLAS proposed a $150 million public share offering, with an option for underwriters to purchase up to $22.5 million more. The company had not announced final pricing or completion at the time of the announcement. A sale would raise capital but increase the number of shares outstanding.

Stock Price Reaction

$SLS closed at $19.15 on Tuesday, November 17, up 156.36% following the trial announcement. It then fell by roughly 10% in after-hours trading after the proposed offering was announced.

Venture Global ($VG) Doubles a China Gas Supply Agreement

Venture Global ($VG) and China Gas expanded an existing liquefied natural gas agreement from 0.5 million to 1.0 million tonnes per year. The newly agreed additional volume is part of a 20-year agreement beginning in 2030. Across their long-term agreements, the companies now have 3.0 million tonnes per year of contracted LNG supply.

Venture Global develops and operates facilities that turn natural gas into a liquid for shipment overseas. Long-term customer agreements can help support these capital-intensive projects by establishing demand years before deliveries begin. Here, the new commitment is the additional 0.5 million tonnes per year; the full 1.0 million-tonne figure includes volume China Gas had already agreed to buy in September. The companies did not disclose pricing, so the announcement does not establish the contract’s expected revenue or profit.

Stock Price Reaction

$VG closed at approximately $12.49 on Tuesday.


This article is for informational purposes only and is not investment advice or a solicitation to buy or sell securities. The content is based on publicly available information and reflects the author’s opinions as of the publication date, which may change without notice. All investments carry inherent risks, including the potential loss of principal, and past performance is not indicative of future results. Forward-looking statements, including references to projected revenues, market trends, or business developments, are based on current expectations and assumptions. Actual results may differ due to various factors, including regulatory changes, economic conditions, competitive pressures, and unforeseen market fluctuations. Readers should conduct their own research or consult a financial advisor before making investment decisions. BBAE holds no position in the securities mentioned, nor are they compensated by the companies mentioned.

Related posts

BBAE AppInvest anywhere, anytimeDownload